Omalizumab use while Breastfeeding
Drugs containing Omalizumab: Xolair
Omalizumab Levels and Effects while Breastfeeding
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
References
Omalizumab Identification
Substance Name
CAS Registry Number
242138-07-4
Drug Class
- Anti-Allergic Agents
- Anti-Asthmatic Agents
- Antibodies, Monoclonal, Humanized
- Antibodies, Anti-Idiotypic
Administrative Information
LactMed Record Number
890
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
2012-10-02
Disclaimer
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
See Also...
- Omalizumab use during Pregnancy
- Omalizumab Consumer Information
- Breastfeeding Support Group
- Safe Medications during Breastfeeding
- Medicine use while Breastfeeding
- Medicine use during Pregnancy
Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.
